Our Pricing

Mounjaro Alternatives UK: Clinical Comparison Guide

Searching for mounjaro alternatives uk comparison data? At Cured Pharmacy, our UK-registered clinical team has assessed thousands of weight loss treatment requests, and we've created this evidence-based guide to help you understand how Mounjaro compares to Wegovy, Saxenda, Orlistat, and emerging oral semaglutide options. Every treatment listed here is available through our online consultation service, with transparent pricing and next-day discreet delivery across the UK.

How Mounjaro Compares to Other GLP-1 Treatments

Mounjaro (tirzepatide) is the UK's first dual GIP/GLP-1 receptor agonist, approved by the MHRA in 2023 for chronic weight management [1]. Unlike single-pathway alternatives such as Wegovy (semaglutide) and Saxenda (liraglutide), tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced metabolic effects.

In the SURMOUNT-1 trial, participants taking the highest Mounjaro dose achieved an average 22.5% body weight reduction over 72 weeks, compared to 14.9% with semaglutide 2.4mg in the STEP-1 trial [1][2]. This dual-action mechanism appears to deliver superior appetite suppression and improved insulin sensitivity, though individual responses vary considerably.

Both Mounjaro and its alternatives require subcutaneous injection, typically in the abdomen, thigh, or upper arm. Mounjaro is administered once weekly using a pre-filled KwikPen, matching the dosing frequency of Wegovy but offering greater convenience than Saxenda, which requires daily injections [3].

Wegovy (Semaglutide): The Established Alternative

Wegovy contains semaglutide 2.4mg, a once-weekly GLP-1 receptor agonist that has been available in the UK since 2022. In clinical practice at Cured Pharmacy, we've observed that Wegovy remains the most prescribed injectable weight loss treatment, largely due to its established safety profile and extensive real-world evidence base.

The STEP clinical trial programme demonstrated that adults taking Wegovy achieved an average 14.9% body weight reduction over 68 weeks, with 83.5% of participants losing at least 5% of their initial weight [2]. Common side effects include nausea, diarrhoea, and constipation, typically most pronounced during dose escalation and diminishing over 4-8 weeks.

Wegovy is particularly suitable for patients who prefer a well-established treatment with predictable tolerability. Our UK prescribers often recommend Wegovy as a first-line option for individuals new to GLP-1 therapy, especially those with concerns about gastrointestinal side effects, as the gradual dose titration schedule allows the body to adapt progressively.

Wegovy Dosing and Titration

Wegovy follows a structured 16-week dose escalation: starting at 0.25mg weekly, increasing to 0.5mg, then 1mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly. This gradual approach minimises gastrointestinal side effects and improves long-term adherence. Your UK prescriber will determine the appropriate titration schedule based on your tolerance and clinical response.

Saxenda (Liraglutide): Daily Injection Option

Saxenda contains liraglutide 3mg, a once-daily GLP-1 receptor agonist that has been licensed in the UK since 2015. Unlike weekly alternatives, Saxenda requires daily subcutaneous injection, which some patients find more manageable for maintaining consistent routine, whilst others prefer the convenience of weekly dosing.

In the SCALE clinical trial programme, participants using Saxenda achieved an average 8% body weight reduction over 56 weeks, with 63.2% losing at least 5% of their baseline weight [4]. Whilst these results are more modest than those observed with Mounjaro or Wegovy, Saxenda remains a valuable option for patients who respond well to daily GLP-1 stimulation or who have previously experienced intolerable side effects with higher-dose weekly injections.

Our clinical experience suggests Saxenda is particularly effective for individuals who benefit from daily medication rituals or who prefer lower peak drug concentrations. The daily dosing allows for more flexible dose adjustments, and patients can temporarily reduce their dose if they experience side effects, then increase again once tolerance improves.

Who Benefits Most from Saxenda

Saxenda may be preferable for patients with sensitive gastrointestinal systems, those who prefer daily routine-based medication, or individuals stepping down from higher-intensity treatments. It's also suitable for patients who have achieved their target weight on weekly injections and wish to transition to a maintenance regimen with more frequent, lower-dose administration.

Oral Alternatives: Wegovy Tablets and Orlistat

For patients who prefer not to inject, two oral alternatives are now available through Cured Pharmacy. Wegovy Oral Tablets contain semaglutide in a tablet formulation that must be taken on an empty stomach with minimal water, waiting 30 minutes before eating or drinking. This delivery method uses an absorption enhancer to facilitate semaglutide uptake through the stomach lining.

Early clinical data suggests oral semaglutide produces weight loss outcomes comparable to the injectable formulation, though adherence to the strict dosing protocol is essential for efficacy [5]. Patients must take the tablet at the same time each morning, with no more than 120ml of water, and avoid food, drink, or other medications for at least 30 minutes afterwards.

Orlistat represents a fundamentally different mechanism: rather than affecting appetite hormones, it inhibits pancreatic and gastric lipases, reducing dietary fat absorption by approximately 30% [6]. Available as prescription-strength Xenical 120mg or lower-dose Alli and Orlos 60mg, orlistat is taken three times daily with meals containing fat. Whilst weight loss is more modest (average 2.9kg additional loss compared to placebo over 12 months), orlistat requires no injection and carries minimal systemic side effects [6].

Side Effect Profiles: What to Expect from Mounjaro Alternatives

All GLP-1 receptor agonists share a common side effect profile, predominantly affecting the gastrointestinal system. In our clinical practice at Cured Pharmacy, approximately 60-70% of patients starting Mounjaro, Wegovy, or Saxenda report mild to moderate nausea during the first 4-8 weeks, with most symptoms resolving as the body adapts [1][2][3].

Mounjaro appears to produce slightly higher rates of gastrointestinal side effects compared to semaglutide, likely due to its dual receptor mechanism. In SURMOUNT-1, 29% of tirzepatide patients reported nausea versus 20% with semaglutide in STEP trials [1][2]. However, these effects are generally transient and can be managed through slower dose titration, eating smaller meals, and avoiding high-fat foods.

Orlistat produces distinctly different side effects: oily spotting, flatulence with discharge, and urgent bowel movements occur when dietary fat intake exceeds 15g per meal [6]. These effects are not harmful but can be socially inconvenient. Our pharmacists recommend patients starting orlistat maintain a food diary to identify their fat tolerance threshold and adjust their diet accordingly.

Managing Side Effects Effectively

Most GLP-1 side effects improve with simple dietary modifications: eating slowly, choosing bland foods during dose escalation, staying well-hydrated, and avoiding lying down immediately after meals. If nausea persists beyond 8 weeks or significantly impacts quality of life, your UK prescriber may recommend maintaining your current dose for an additional 4 weeks before increasing, or switching to an alternative treatment with better individual tolerability.

Choosing the Right Mounjaro Alternative for Your Situation

Treatment selection depends on multiple factors beyond efficacy data: your BMI and weight loss goals, previous medication experience, tolerance for injections, daily routine, budget considerations, and any contraindications in your medical history. At Cured Pharmacy, our UK-registered prescribers conduct a comprehensive clinical assessment during your free online consultation to determine the most appropriate option.

Generally, Mounjaro offers the highest average weight loss but requires tolerance of its side effect profile and higher cost. Wegovy provides an excellent balance of efficacy and established safety data. Saxenda suits patients preferring daily dosing or requiring flexible dose adjustments. Oral semaglutide offers injection-free convenience for those willing to follow strict dosing protocols, whilst orlistat remains the most affordable option with a completely different mechanism.

All prescription weight loss treatments should be used alongside a reduced-calorie diet and increased physical activity. NICE guidelines recommend considering pharmacological intervention when BMI is 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as type 2 diabetes or hypertension [7]. Your prescriber will verify your eligibility during the online consultation, which takes under 3 minutes to complete and includes review by our superintendent pharmacist, Tarun Kumar (GPhC 2233073).

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
5. Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and physical activity levels.